Regional treatment for axillary lymph node micrometastases of breast cancer.
[Regional treatment for axillary lymph node micrometastases of breast cancer]. Cancer Radiother. 2015 May 22; Authors: Houvenaeghel G, Cohen M, Jauffret-Fara C, Bannier M, Chéreau-Ewald É, Rua Ribeiro S, Lambaudie É Abstract In patients with breast cancer, axillary lymph node micrometastasis detection has been more frequent with a better definition since the introduction of the sentinel node procedure. In this review, we focus on pN1mi micrometastasis and review the literature in order to determine factors involved in making the decision of a regional treatment. PMID: 26006761 [PubMed - as supplied by publisher]
Analyst, 2021, Accepted Manuscript DOI: 10.1039/D1AN01071A, PaperHuiying Xu, Lu Zheng, Yu Zhou, Bang-Ce Ye Tumor-related exosomes, which are heterogeneous membrane-enclosed nanovesicles shed from cancer cells, have been widely recognized as potential noninvasive biomarkers for early cancer diagnosis. Herein, an artificial enzyme cascade amplification strategy... The content of this RSS Feed (c) The Royal Society of Chemistry
Background: In a previous exploratory study, we reported lower concentrations of the ovarian reserve biomarker anti-Müllerian hormone (AMH) in adulthood with prenatal farm exposure. We now examine this association as well as childhood farm exposure using enrollment data from the Sister Study, a large US cohort of women. Methods: We collected prenatal and childhood farm exposure data by questionnaire and telephone interview. However, serum AMH data were available only for a nested subset: premenopausal women ages 35–54 subsequently diagnosed with breast cancer (n = 418 cases) and their matched controls...
Increasing numbers of women who need MRI screening for breast cancer are being hit by high out-of-pocket costs, a new study finds.Reuters Health Information
This marks the fourth clearance for Volpara ’s breast health platform since its original authorization back in 2010.
Conditions: Breast Cancer; Sentinel Lymph Node Biopsy; Neoadjuvant Therapy Intervention: Procedure: SLNB + ALND Sponsor: National Cheng-Kung University Hospital Active, not recruiting
Conditions: ER+ Breast Cancer; HER2-negative Breast Cancer Interventions: Drug: Palbociclib 125Mg Tab; Drug: Fulvestrant injection; Drug: Tamoxifen; Drug: Letrozole; Drug: Exemestane; Drug: Anastrozole Sponsors: Royal Marsden NHS Foundation Trust; Pfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting
Condition: Operable Breast Neoplasms Intervention: Other: prediction of overall survival using Web based PREDICTV2.0 portal Sponsor: Tata Memorial Centre Recruiting
Condition: Breast Cancer Intervention: Drug: abemaciclib Sponsor: Hellenic Cooperative Oncology Group Recruiting
Expert Rev Mol Diagn. 2021 Aug 2. doi: 10.1080/14737159.2021.1962707. Online ahead of print.ABSTRACTINTRODUCTION: Breast cancer (BC) is the most significant threat to women's life. To demonstrate its molecular mechanisms, which results in BC progression, it is crucial to develop approaches to enhance prognosis and survival in BC cases.AREAS COVERED: In the current study, we aimed to highlight the updated data on the oncogenic and tumor suppressive roles of lncRNAs in the progression of various subtypes of BC by specifically putting importance on the functional characteristics, modulatory agents, therapeutic potential, futu...